 Home > Active Ingredient News > Study of Nervous System > JNNP: The effect of alemtuzumab on the efficacy and safety outcomes of patients with multiple sclerosis

JNNP: The effect of alemtuzumab on the efficacy and safety outcomes of patients with multiple sclerosis

 Last Update: 2021-04-13
 Source: Internet
 Author: User

Tags

tymlos side effects

lovibond scale

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Although some disease-modified therapies (DMTs) have been approved in the past decade, the treatment of relapsing-remitting multiple sclerosis remains challenging.

Alemtuzumab (ALEM) is an anti-CD52 monoclonal antibody that has been shown to control in untreated patients (CARE-MS I) and patients with poor response to first-line DMT (CARE-MS II) Very effective in disease activity.

Management consensus However, in patients who previously did not respond to fingolimod (FTY), the evidence for the effectiveness of ALEM has been conflicting.

Eleven adult patients with active MS who were considered eligible for ALEM treatment according to the latest prescribing standards were included in the prospective planned cohort study (NCT04082260).

immunity

Clinical data is also needed to assess the potential impact of DMT sequencing on the immune system to assist the decision-making process in clinical practice.

Blood vessel

170 patients who did not respond to NTZ, FTY, IFN or DMF at the beginning of treatment or before were identified and received at least two courses of ALEM treatment.

Regression analysis showed that among all the previously used DMT, the Fingemod pretreatment group (first relapse time n=33 hours (HR 5.

In a medical setting, this article proves that patients who have previously received Fengliemod have poor disease control after alemtuzumab treatment, and the risk of secondary autoimmunity is increased.

PfeufferS ,RuckT ,PulR PfeufferSPfeuffer RuckTRuck PulRPul, et albmj.
com/content/early/2021/03/11/jnnp-2020-325304" target="_blank" rel="noopener">Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumabJournal of Neurology, Neurosurgery & Psychiatry Published Online First: 12 March 2021.
Published Online First: doi: 10.
1136/jnnp-2020-325304doi:Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.